Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells

Rajpal S. Burmi, Elaina N. Maginn, Hani Gabra, Euan A. Stronach & Harpreet S. Wasan

To cite this article: Rajpal S. Burmi, Elaina N. Maginn, Hani Gabra, Euan A. Stronach & Harpreet S. Wasan (2018): Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells, Cancer Biology & Therapy, DOI: 10.1080/15384047.2018.1504718

To link to this article: https://doi.org/10.1080/15384047.2018.1504718
Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells

Rajpal S. Burmi, Elaina N. Maginn, Hani Gabra, Euan A. Stronach, and Harpreet S. Wasan

Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Clinical Discovery Unit, Early Clinical Development, AstraZeneca, Cambridge, United Kingdom

ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) progression and chemotherapy insensitivity have been associated with aberrant PI3K/mTOR/MEK signalling. However, cell death responses activated by inhibitors of these pathways can differ – contextually varying with tumour genetic background. Here, we demonstrate that combining the dual PI3K/mTOR inhibitor PF5212384 (PF384) and MEK inhibitor PD325901 (PD901) more effectively induces apoptosis compared with either agent alone, independent of KRAS mutational status in PDAC cell lines. Additionally, a non-caspase dependent decrease in cell viability upon PF384 treatment was observed, and may be attributed to autophagy and G0/G1 cell cycle arrest. Using reverse phase protein arrays, we identify key molecular events associated with the conversion of cytostatic responses (elicited by single inhibitor treatments) into a complete cell death response when PF384 and PD901 are combined. This response was also independent of KRAS mutation, occurring in both BxPC3 (KRAS wildtype) and MIA-PaCa-2 (KRASG12D mutated) cells. In both cell lines, Bim expression increased in response to PF384/PD901 treatment (by 60% and 48%, respectively), while siRNA-mediated silencing of Bim attenuated the apoptosis induced by combination treatment. In parallel, Mcl-1 levels decreased by 36% in BxPC3, and 30% in MIA-PaCa-2 cells. This is consistent with a functional role for Mcl-1, and siRNA-mediated silencing enhanced apoptosis in PF384/PD901-treated MIA-PaCa-2 cells, whilst Mcl-1 overexpression decreased apoptosis induction by 24%. Moreover, a novel role was identified for PDCD4 loss in driving the apoptotic response to PF384/PD901 in BxPC3 and MIA-PaCa-2 cell lines. Overall, our data indicates PF384/PD901 co-treatment activates the same apoptotic mechanism in wild-type or KRAS mutant PDAC cells.

Introduction
Pancreatic ductal adenocarcinoma (PDAC) has a global incidence of > 85,000 cases yearly and has one of the poorest prognoses, with an age-standardised 5-year survival of 3.7%.1,2 The lack of efficacy of current chemotherapy options (gemcitabine, FOLFIRINOX and Nab-paclitaxel), and the rapid emergence of resistance to these regimens, highlights the need for developing targeted therapeutic strategies for this malignancy. Although this has largely been hampered by the lack of identification of key actionable pathogenic drivers in PDAC, there has recently been progress in understanding the genetic signature of PDAC, which should lead to new therapies.3,4,7 It is well documented that the KRAS gene is mutated in ~ 90% of PDAC and is thought to be an early and initiating event, which in combination with cooperative genetic alterations (TP53, CDKN2A and SMAD4) is sufficient to drive the formation of premalignant lesions into PDAC.8 Ras pathway alterations are common in most cancers and have been identified as important drivers of oncogenesis, for example in high-grade serous ovarian cancers.9 While a number of pharmacological approaches have sought to block Ras-Raf-MEK-ERK signalling, direct inhibition of the K-Ras protein has been unsuccessful clinically and efforts have instead focused on targeting downstream signalling proteins, such as Raf, MEK and Akt.10

Targeting Ras signalling via MEK inhibition is a logical strategy but trials have demonstrated no clinical benefit as monotherapy.11-16 Many PI3K/Akt/mTOR inhibitors are undergoing clinical development, but their efficacy may be limited by the induction of compensatory pro-oncogenic MEK signalling.17-19 Therefore there is a strong rationale for combining inhibitors of both pathways, and a number of preclinical studies have demonstrated improved efficacy by combining either PI3K and/or mTOR inhibitors with a MEK inhibitor in various tumour types.20-22 Studies to identify potential molecular biomarkers of response to these agents have largely focused on genomic aberrations in KRAS and PIK3CA. However, these alone do not appear to be absolute predictive markers of response.23-29 Defining the cell death pathways activated by these inhibitors may suggest additional response biomarkers. There is preliminary but equivocal

CONTACT Elaina N. Maginn e.maginn@imperial.ac.uk

**These authors contributed equally to this work.

© 2018 The Author(s). Taylor & Francis Group, LLC
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
evidence that PI3K/mTOR/MEK inhibitor-induced changes in the expression of Bim and Mcl-1 proteins are related to KRAS mutational status. In part the ambiguity surrounding this may relate to specific cancer types. For example, mTOR inhibition has been found to decrease expression of Mcl-1 in colorectal cancer cells, but only when KRAS mutations were present. In comparison, the dual PI3K/mTOR inhibitor BEZ235 had no effect on Mcl-1 expression in PDAC cell lines irrespective of KRAS status, but reduced expression in ovarian cancer cell lines. Additionally, while MEK inhibition is more commonly reported to increase or stabilise expression of Bim, it has also been reported by some to modulate Mcl-1 stability. The synergy observed when PI3K/mTOR/MEK inhibitors are combined may stem from Bim induction alongside Mcl-1 decrease, but the primary regulators of these alterations may differ due to the cancer type and the inhibitor used. Therefore it is important to understand how specific agents contribute to the induction of cell death in individual cancer types.

Despite clinical evaluation and phase I trial activity, there are currently no licensed indications for dual PI3K/mTOR inhibitors. The induction of compensatory MEK signalling following PI3K/mTOR inhibition provides a strong rationale for combining with MEK inhibitors to enhance therapeutic efficacy. Indeed, a phase 1 trial combining PF5212384 (PF584, dual PI3K/mTOR inhibitor with PD325901 (PD901, non-ATP competitive MEK inhibitor) has been completed (NCT01347866), although results have not been published thus far. In the present study, we use reverse phase protein array (RPPA) analysis to compare the differential effects, with respect to response and apoptotic signatures, of PF384 and PD901 combination treatment between KRAS mutant and wild-type PDAC cell lines.

**Results**

We have previously used RPPA analysis to define a biomarker signature for clinical response to AKT inhibition in the context of platinum re-sensitisation. Here, we apply this technology to investigate the response of PDAC cell lines to PF384 and PD901, alone and in combination. BxPC-3 and MIA-PaCa-2 cells were treated for 6 hours with vehicle control (DMSO), 1 μM PF384, 0.1 μM PD901 or both drugs in combination, after which whole cell lysates were subject to expression analysis of 214 proteins (Table S1). As shown in Figure 1a, the response of a panel of PI3K/mTOR/MEK signalling components to these inhibitors is consistent with their on-target effects, although some cross-regulation of these pathways by these agents was observed. Indicative of
PI3K inhibition, treatment with PF384 abrogated phospho-S473AKT (p^S473AKT) expression by 80% in BxPC3 cells. Expression of phospho-S2448mTOR (p^S2448mTOR) and phospho-T389p70-S6K (p^T389p70-S6K) were also decreased by 60% and 90%, respectively, indicating mTOR inhibition. In comparison, PD901 did not affect expression of p^S473AKT in this cell line and decreased the expression of p^S2448mTOR and p^T389p70-S6K to much lesser extents (20% and 50%, respectively). MEK signalling, as indicated by phospho-T202/Y204MAPK (p^T202/Y204MAPK) expression was decreased by 30% in response to PF384, but by 60% following treatment with PD901. In MIA-PaCa-2 cells, treatment with PF384 had a reduced inhibitory effect on PI3K signalling (compared with BxPC3 cells) with p^S473AKT levels decreasing by 40% – and they remained unaffected by PD901 treatment. Levels of p^S2448mTOR and p^T389p70-S6K were decreased in response to PF384 to similar extents as in BxPC3 cells, with reductions of 50% and 90%, respectively. Again, PD901 had a reduced effect on these signalling components with observed reductions of 20% and 40%, respectively. With respect to inhibition of MEK signalling in MIA-PaCa-2 cells, p^T202/Y204MAPK expression was found to be decreased by 40% following treatment with PD901, but increased 2-fold in response to PF384. Although our data indicates successful inhibition of PI3K/mTOR by PF384 and MEK signalling by PD901 in BxPC3 and MIA-PaCa-2 cell lines, treatment for 6 hours with these agents induced minimal apoptosis in either cell line (Figure 1b). By comparison, when PF384 and PD901 were combined, apoptosis was significantly increased compared with single agent responses, to 6.6-fold in BxPC3 cells (p < 0.0001) for which a combination index (CI) of 0.55, indicating synergy, was calculated. In MIA-PaCa-2 cells, the 4.3-fold apoptosis induction measured following co-treatment with PF384 and PD901 was twice that induced by PF384 alone, and significantly higher compared to that induced by PD901 single treatment (p < 0.05) with a CI of 0.86 again indicating synergy. Extending the time of treatment to 24 hours and to additional cell lines, a similar response profile was observed: as shown in Figure 2, the combination of PF384 and PD901 induced the highest level of apoptosis in a panel of PDAC cell lines (BxPC3, MIA-PaCa-2, Panc-1, and Panc05.04). Relative to that induced by single agent treatments, apoptosis in response to this combination treatment was significantly higher and synergistic (BxPC3 CI = 0.3; MIA-PaCa-2 CI = 0.88; Panc05.04 CI = 0.62) in all but the Panc-1 cell line (CI = 1.17).

In addition to apoptosis, we hypothesised whether the inhibitors used may also affect cell viability or growth via other mechanisms. As shown in Figure 3a, both BxPC3 and MIA-PaCa-2 cells were found to arrest in the G0/G1 phase of the cell cycle in response to 24 hours treatment with PF384, and this was accompanied by a reduction in the S- and G2/M-phase populations. In response to PD901 treatment for the same time, G0/G1 arrest was also observed in both cell lines, although to a slightly greater extent in MIA-PaCa-2 cells. Following co-treatment with PF384 and PD901, the cell cycle populations showed a distribution similar to those obtained following single agent PF384 treatment. Consistent with these findings, reduced BxPC3 (14%) and MIA-PaCa-2 (17%) cell viability was observed after treatment with PF384 for 6 hours (Figure 3b). This was decreased by a further 8% when PF384 was combined with PD901. In comparison, PD901 treatment alone minimally affected cell viability. Together this data suggested that growth arrest or non-caspase-associated cell death might result from PF384 treatment. In support of a contribution of non-caspase-associated cell death to PDAC cell line response to PF384 treatment, the decrease in BxPC3 and MIA-PaCa-2 cell viability induced by PF384 or PF384/PD901 was not restored to that of control levels when the cells were pretreated with the pan-caspase inhibitor z.VAD.fmk (100 μM). In fact, when compared to non-caspase inhibited cells, the viability decrease was enhanced – by an average of 19% in BxPC3 cells and 13% in MIA-PaCa-2 cells in the presence of z.VAD.mk (Figure 3b). Due to the established role of mTOR in autophagy, we investigated whether activation of this process may account for the above observation. In support of this, the autophagy marker LC3A/B-II was found to be increased in response to the 6 hour treatment with PF384, either alone or in combination with PD901 (Figure 3c), and
this was accompanied by a concomitant reduction in LC3A/B-1 expression.

To identify mechanistic drivers of response to combination PI3K/mTOR and MEK inhibition, we mined our proteomic data for alterations, which may account for the apparent synergistic apoptotic phenotype observed on combining PF384 and PD901. For this we also included data from an ovarian cancer cell line, PEA2 (Fig S1, Table S1), for comparison between cancer types. The majority of proteins with significantly altered expression under combination treatment conditions were, unsurprisingly, related to PI3K/mTOR/MEK signalling. Excluding these, pro-apoptotic protein Bim was found to be among the top 5 proteins whose expression was significantly increased in all cell lines in response to PF384/PD901 (relative to DMSO treated cells). As shown in Figure 4a, Bim expression increased in BxPC3 cells by 56% (p ≤ 0.0001) after treatment with this combination, and although also significantly increased by single agents, this was not by more than 28% (p ≤ 0.0001) for either drug. For MIA-PaCa-2 cells, Bim expression increased by 48% (p ≤ 0.001) after PF384/PD901 treatment, whilst a 38% increase (p ≤ 0.01) was noted in response to PD901 alone. Consistent with this, western blotting found levels of Bim (Bim\(\text{EL}\), the predominant isoform was detected using this antibody) to be increased on treatment with PD901 alone or in combination with PF384 in these cell lines (Figure S1). Also noted was a mobility shift of Bim in MIA-Pa-Ca-2, which may represent a change in phosphorylation status. In PEA2 cells, a significant increase in Bim expression of 36% (p ≤ 0.01) was also detected in response to PF384/PD901 co-treatment from the RPPA data. Confirmation of a role for Bim in driving PF384/PD901-induced apoptosis was assessed using siRNA in MIA-PaCa-2 cells as a representative model. As shown in Figure 4b, the silencing of Bim attenuated the apoptosis...
induced in response to PF384/PD901 co-treatment, albeit not significantly.

Bim-induced apoptosis is often associated with a reduction in levels of the anti-apoptotic protein Mcl-1, including in response to PI3K/Akt/mTOR inhibition, and indeed our RPPA data (Figure 4c) indicated a significant decrease ($p \leq 0.0001$) in Mcl-1 expression in all assessed cell lines (BxPC3 36%, MIA-PaCa-2 30% and PEA2 43%) following PF384/PD901 co-treatment. These decreases were also observed in response to single agent treatment (except for PD901 in PEA2 cells). Confirmation of these responses in PDAC cells by western blotting confirmed this reduction of Mcl-1, with the greatest decrease observed in response to PF384/PD901 co-treatment (Figure S2). We also note an additional band, possibly corresponding to the short 32kDa form of Mcl-1 in MIA-PaCa-2 cells only, and this followed a similar pattern of regulation in response to PF384/PD901 treatment. However, siRNA-mediated silencing of Mcl-1 was found to only enhance the apoptotic response of MIA-PaCa-2 cells to the combination treatment (Figure 4d). Conversely, overexpression of Mcl-1 in this cell line (Figure 4e) resulted in a 24% decrease in apoptosis induction, relative to vector control, in response to the combination treatment. These results are consistent with a functional role for Mcl-1 in the apoptotic phenotype observed on combination of PI3K/mTOR and MEK inhibitors.
In this study we identify a novel role for PDCD4 in the cell death mechanism activated when PDAC cells are co-treated with the PI3K/mTOR inhibitor PF384 and the MEK inhibitor PD901. Additionally, our data indicates roles for Bim and Mcl-1 in regulating PDAC response to this combination irrespective of KRAS mutation status. Due to the complexity and co-dependency of cancer cell survival networks, it is not surprising that combining inhibitors of these critical signalling nodes achieved a far greater level of tumour cell kill than single agent treatments. While this is reflective of preclinical and clinical studies demonstrating the improved efficacy of combining PI3K and/or mTOR inhibitors with a MEK inhibitor in PDAC, and other cancer types, our study indicates that the mechanism(s) underpinning this may be inhibitor-specific. Defining these may assist in developing theranostic biomarkers for future development of such inhibitors for treating PDAC.

In line with previous studies, our RPPA data confirms a role for Bim and Mcl-1 in the apoptotic pathway induced in response to PI3K/mTOR/MEK co-inhibition. Although in our study this did not differ between KRAS mutant and wild-type PDAC cell lines (and was also the same in the KRAS wild-type ovarian cancer PEA2 cell line), we note some differences with other studies regarding the extent to which each inhibitor affects each protein. Reports of MEK inhibition leading to increased expression and stabilisation of Bim have generally been consistent, across various tumour and inhibitor types, regardless of KRAS mutation status. Consistent with this, we found expression of pro-apoptotic Bim to be increased in both BxPC3 and MIA-PaCa-2 cells in response to PD901. By comparison, the effect of the dual PI3K/mTOR inhibitor on Bim expression can vary between cell types, although this is reportedly not KRAS related. Of interest however, while Venkannagari et al., reported that BEZ235 (another dual PI3K/mTOR inhibitor) treatment increased Bim expression in both BxPC3 and MIA-PaCa-2 cells, our study suggests that PD901 may be a useful agent to achieve this in a broad spectrum of PDAC cases. Additionally, our RPPA data also hints that PF384/PD901-induced cell cycle arrest may be related to Mcl-1 downregulation as both increasing in BxPC3 and MIA-PaCa-2 under all treatment conditions. Despite the paradox, as shown in Figure 5a, siRNA-mediated silencing of PDCD4 significantly increased PF384/PD901-induced apoptosis in MIA-PaCa-2 cells 1.8-fold, relative to that measured in PF384/PD901-treated mock-transfected cells.

**Discussion**

In this study we identify a novel role for PDCD4 in the cell death mechanism activated when PDAC cells are co-treated with the PI3K/mTOR inhibitor PF384 and the MEK inhibitor PD901. Additionally, our data indicates roles for Bim and Mcl-1 in regulating PDAC response to this combination irrespective of KRAS mutation status. Due to the complexity and co-dependency of cancer cell survival networks, it is not surprising that combining inhibitors of these critical signalling nodes achieved a far greater level of tumour cell kill than single agent treatments. While this is reflective of preclinical and clinical studies demonstrating the improved efficacy of combining PI3K and/or mTOR inhibitors with a MEK inhibitor in PDAC, and other cancer types, our study indicates that the mechanism(s) underpinning this may be inhibitor-specific. Defining these may assist in developing theranostic biomarkers for future development of such inhibitors for treating PDAC.

In line with previous studies, our RPPA data confirms a role for Bim and Mcl-1 in the apoptotic pathway induced in response to PI3K/mTOR/MEK co-inhibition. Although in our study this did not differ between KRAS mutant and wild-type PDAC cell lines (and was also the same in the KRAS wild-type ovarian cancer PEA2 cell line), we note some differences with other studies regarding the extent to which each inhibitor affects each protein. Reports of MEK inhibition leading to increased expression and stabilisation of Bim have generally been consistent, across various tumour and inhibitor types, regardless of KRAS mutation status. Consistent with this, we found expression of pro-apoptotic Bim to be increased in both BxPC3 and MIA-PaCa-2 cells in response to PD901. By comparison, the effect of the dual PI3K/mTOR inhibitor on Bim expression can vary between cell types, although this is reportedly not KRAS related. Of interest however, while Venkannagari et al., reported that BEZ235 (another dual PI3K/mTOR inhibitor) treatment increased Bim expression in both BxPC3 and MIA-PaCa-2 cells, our study suggests that PD901 may be a useful agent to achieve this in a broad spectrum of PDAC cases. Additionally, our RPPA data also hints that PF384/PD901-induced cell cycle arrest may be related to Mcl-1 downregulation as both increasing in BxPC3 and MIA-PaCa-2 under all treatment conditions. Despite the paradox, as shown in Figure 5a, siRNA-mediated silencing of PDCD4 significantly increased PF384/PD901-induced apoptosis in MIA-PaCa-2 cells 1.8-fold, relative to that measured in PF384/PD901-treated mock-transfected cells.

With regards to Mcl-1 expression, we found it to be decreased in response to PI3K/mTOR inhibition in all cell lines. This is in contrast to studies using other inhibitors which found no effect, or a decrease only in KRAS mutant cells. Although anti-apoptotic Mcl-1 is highly expressed in many cancers including pancreatic tumours and therefore an attractive therapeutic target, it appears that strategies to decrease/inhibit it are cell-type specific, highlighting the importance of defining molecular mechanisms specific to both individual inhibitor and tumour type. Our present study suggests that PF384 may be a useful agent to achieve this in a broad spectrum of PDAC cases. Additionally, our RPPA data also hints that PF384/PD901-induced cell cycle arrest may be related to Mcl-1 downregulation as both KRAS mutant and wild-type PDAC cell lines p27 levels were found to be increased (Table S1) and this may parallel a study in colorectal cancer cells in which cell cycle arrest has been associated with elevated p27 levels following Mcl-1 loss. Our RPPA analysis also suggests STAT3, whose inhibition has previously been shown to reduce Mcl-1 levels and induce apoptosis in PDAC cells in vitro, as a possible effector of PI3K/mTOR/MEK-mediated Mcl-1 regulation as in MIA-PaCa-2 cells levels of STAT3 were significantly reduced in response to all treatments (Table S1).

Contrary to its role as a tumour suppressor, we found expression of PDCD4 to be downregulated in response to PF384/PD901 treatment. Decreased expression of this protein has widely been correlated with tumour progression and poor
outcomes in a range of cancer types, including pancreatic and ovarian, with its tumour suppressive effect being largely attributed to regulating cell cycle progression past G1, as well as apoptosis and autophagy.\textsuperscript{31,45-49} However, in response to mitogenic signals, PDCD4 can undergo PI3K/Akt/mTOR driven proteasomal degradation\textsuperscript{49-51} and decreased expression of this protein has been associated with chemoresistance.\textsuperscript{52} Therefore our data indicating that the siRNA-mediated suppression of PDCD4 increases apoptotic response to PF384/PD901 treatment was surprising and we speculate this is related to a PI3K-independent and lesser known role for PDCD4 in suppressing pro-caspase-3 translation.\textsuperscript{53} Such a role for PDCD4 in driving PI3K/mTOR/MEK inhibitor-induced apoptosis has not previously been reported, and additional studies to establish this role of PDCD4 in our system may clarify its potential as a novel therapeutic target or biomarker in PDAC. For example, the function of PDCD4 may be dependent on levels of interacting proteins such as PRMT5.\textsuperscript{54} Alternatively, it is possible that the decreased PDCD4 expression in our RPPA data is the result of increased mir-21 expression: mir-21, an established PDCD4 repressor,\textsuperscript{55} can be upregulated by COX-2\textsuperscript{56} which we found to be significantly increased in BxPC3 and PEA2 cells treated with PF384 (Table S1).

In addition to confirming that a greater apoptotic response is elicited in PDAC cells when the PI3K/mTOR inhibitor PF384 and the MEK inhibitor PD901 are used simultaneously, compared with inhibition of either pathway in isolation, we found that single agent PF384 or PD901 treatment results in G0/G1 cell cycle arrest. This is consistent with previous reports indicating a mechanism of cytostatic response in PDAC cells following PI3K/mTOR or MEK inhibition.\textsuperscript{26,29,31,57,58} Although this may account for the lack of cell death induced by these agents, our data also suggests autophagy induction in BxPC3 and MIA-PaCa-2 cells following PI3K/mTOR inhibition with PF384. The presence of autophagy in pancreatic malignancies has been investigated, although its role in promoting or suppressing tumour cell survival appears to be context dependent.\textsuperscript{59} Autophagic responses have previously been associated with PDAC resistance to PI3K/mTOR inhibitors,\textsuperscript{60,61} and our data supports this correlation: the increase in LC3A/B-II observed in response to PF384 was more pronounced in MIA-PaCa-2 cells which showed no apoptotic response to this drug, compared with BxPC3 cells in which a 3-fold increase in apoptosis was measured after 24 hour treatment. Interestingly however, our RPPA data indicated that mTOR expression was reduced by similar levels in both cell lines following PF384 treatment. One possible explanation for this could be the inhibition of an mTOR-independent, PI3K-driven autophagy pathway\textsuperscript{62} in BxPC3 cells. Given that viability in both cell lines decreased to similar extents in response to PF384, this appears unlikely however. Alternatively this may be the result of increased FOXO3a levels in PF384 treated-MIA-PaCa-2 cells (Table S1), which have been shown to drive LC3 expression,\textsuperscript{63} or may be related to the incompletely understood association of KRAS mutational status with autophagy induction.\textsuperscript{59} However, regardless of differences in autophagic molecular responses, our data indicates activation of this process in both KRAS mutant and wild-type PDAC cell lines in response to PF384.

Although there are important roles for PI3K/Akt/mTOR and Ras/MEK signalling pathways in PDAC progression and chemosensitivity, the most effective method of exploiting these for therapeutic gain remains unclear. A myriad of inhibitors targeting these pathways are available and their efficacy and mechanism of action is likely linked to structure and tumour type.\textsuperscript{19,64} Additionally, the compensatory cross-regulation of these pathways highlights the importance of selecting the right combination, and possibly right sequence, for the right tumour. Our data indicates that in PDAC cell lines, the response to PF384 and PD901 is independent of KRAS status. Although G0/G1 cell cycle arrest and autophagy are induced following PI3K/mTOR inhibition, the conversion of these to a complete cell death response is greatest when both inhibitors are combined and involves the modulation of the Bim/Mcl-1 apoptotic axis. Additionally we suggest a new role for PDCD4 in eliciting cell death in response to this combination of agents.

**Materials and methods**

**Cell lines and reagents**

BxPC-3 (93120816; KRAS wild-type), MiaPaCa-2 (85062806; KRAS\textsuperscript{G12C} mutated) and Panc-1 (87092802; KRAS\textsuperscript{G12D} mutated) cells lines were purchased from the Health Protection Agency Culture Collections and Panc05.04 cells (CRL-2557; KRAS\textsuperscript{G12D} mutated) were purchased from the American Type Culture Collection. PEA2 cells\textsuperscript{65} (KRAS wild-type) were obtained from Dr. Simon Langdon (University of Edinburgh, UK). BxPC-3 and PEA2 cells were maintained in RPMI-1640 (Sigma, R5886), and Mia-Pa-Ca-2 and Panc-1 in DMEM (Sigma, D5546), supplemented with 10% fetal calf serum (First Link UK, 02–00–850), 2 mM L-glutamine (Thermo Fisher, 25030–024) and penicillin/streptomycin (50 units/ml and 50 μg/ml respectively; Thermo Fisher, 15070–063). Panc05.04 cells were maintained in RPMI-1640 supplemented with 15% fetal calf serum, plus 2 mM L-glutamine and penicillin/streptomycin. Cells were routinely tested for mycoplasma, and their authenticity confirmed by STR analysis. The PI3K/mTOR inhibitor PF5212384 (PF384) was a gift from Pfizer (UK), the MEK inhibitor PD325901 (PD901) was purchased from Selleck Chemicals (S1036), and the caspase inhibitor Z-VAD-FMK was from R&D (FMK001). All inhibitors were reconstituted in DMSO (Sigma, 276855) and stored at −20°C. Primary antibodies were used according to manufacturers’ instructions and their Antibody Registry IDs are as follows: from Cell Signaling Technology anti-LC3-A/B (AB_2137703), anti-Mcl-1 (AB_2281980), anti-Bim (AB_659953) and anti-PDCD4 (AB_2162318); from Sigma anti-β-tubulin (AB_477577). For cell cycle analysis, propidium iodide was purchased from Sigma (P4170) and RNase A was from Qiagen (19101).

**RPPA analysis**

Cells were seeded to 70% confluency and allowed to adhere overnight before being treated with either 1 μM PF384 alone or in combination with 0.1 μM PD901 for 6 hours. Cells were then washed in PBS and RPPA lysis buffer added (1% Triton X-100, 50 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl\textsubscript{2}, 1 mM EGTA, 100 mM NaF, 10 mM sodium
pyrophosphate, 1 mM Na₂VO₄, 10% glycerol, containing freshly added protease (Roche Applied Science, 04693159001) and phosphatase inhibitors (VWR, EM524628)). Cells were incubated on ice with the buffer for 20 minutes before scraping and centrifuging (14,000 rpm, 10 minutes, 4°C) and the supernatant collected. RPPA assay was performed at the Functional Proteomics RPPA Core Facility at MD Anderson, as previously described. Data provided from the RPPA facility consisted of protein intensity values normalised to the loading control and transformed to linear values (normalised linear) which were used to calculate relative significant fold expression.

**Apoptosis and cell viability assays**

Cells were seeded at a density of 5000 cells/well in a 96 well plate and allowed to adhere overnight before being treated with inhibitors. When required, cells were treated with the caspase inhibitor Z-VAD-FMK one hour prior to co-treatment with other agents. All treatments were performed at 37°C 5% CO₂ for the durations indicated. Apoptosis was measured by detection of active caspase-3/7 using the Caspase Glo 3/7 assay (Promega, G8090) according to the manufacturer’s instructions. Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays (Sigma, M5655) and as previously described, caspase activity was normalised to viability data for each treatment to correct for cell density and to determine overall apoptosis levels.

**Cell cycle analysis**

Cells were seeded in 6 well plates to 70% confluency and allowed to adhere overnight before being treated as required. After trypsinisation and harvesting, cells were resuspended in PBS before being fixed in ice cold 90% ethanol. Cells were stored at 4°C overnight or until required. For DNA staining, cells were pelleted and resuspended in 25 μg/ml propidium iodide solution containing 0.4 μg/ml RNase A and incubated at 37°C for 1.5 hours. Analysis was performed using a FACSCalibur Flow Cytometer (BD Biosciences) and data processed using FlowJo software (FlowJo, LLC).

**Immunoblotting**

Cells were seeded in 6 well plates to approximately 70% confluency and allowed to adhere overnight before being subject to the appropriate treatment for the indicated duration. Cells were then trypsinised and together with the residual medium were pelleted before being washed in ice cold PBS, and final cell pellet resuspended in RIPA Lysis buffer (Santa Cruz, sc-24948) according to the manufacturer’s instructions. An equal quantity of the clarified protein lysate was then subject to western blotting as described previously.

**siRNA-mediated gene silencing**

Cells were seeded in 6 well plates to 50–60% confluency and allowed to adhere overnight before being transfected with 100 nM final concentration siRNA (GE Healthcare, L-004383–00, L-004501–00, L-004438–00, equivalent non-targeting siRNA control (GE Healthcare, D-001810–10-05) or transfection reagent alone. Transfections were carried out using DharmaFECT1 (GE Healthcare, T-2001) as per manufacturer instructions. 48 hours post-transfection, cells were trypsinised and reseeded into 96 well plates and left to adhere overnight prior to inhibitor treatment and subsequent apoptosis and viability assays.

**Mcl-1 overexpression**

The vector pcDNA3.1 containing the MCL1 gene (pcDNA3.1-hMCL1 Addgene plasmid #25375) and control vector pcDNA3.1: hygro(+) (Thermo Fisher, V87020) were ampliﬁed in bacterial cells (Bioline, BIO-85027) and puriﬁed using a plasmid puriﬁcation kit (Qiagen, 12162). These were then transfected into cells, seeded in 6 well plates to 50–60% confluency and allowed to adhere overnight, using Effectene transfection reagent (Qiagen, 301425), according to manufacturer instructions. 24 hours post-transfection, cells were trypsinised and reseeded into 96 well plates for inhibitor treatment and subsequent apoptosis and viability assays.

**Statistical and combination index analysis**

Statistical analysis and data visualisation were performed using GraphPad Prism 6 (GraphPad). Combination indices (CI) were calculated using the response additivity model with CI = (effect of drug A + effect of drug B)/(effect of combination treatment). Where CI< 1, a greater effect than an expected additive effect is indicated.

**References**

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon (France): International Agency for Research on Cancer; 2013. accessed on 22/09/2017. Available from http://globocan.iarc.fr
2. Cancer Research UK. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/survival#heading-Zero. Accessed 13/09/2017.
3. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501. doi:10.1038/nature14169.
4. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52. doi:10.1038/nature16965.
5. Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32(2):185–203.e13. doi:10.1016/j.ccel.2017.07.007.
6. Pei Jin ME, Garvin T, Bailey P, Waddell N, Chang DK, Kelley DR, Shuai S, Gallinger S, McPherson JD, Grimmond SM, et al. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nat Genet. 2017;49(6):825–833. doi:10.1038/ng.3861.
7. Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, et al. Hypermutation in pancreatic cancer. Gastroenterology. 2017;152(1):68–74.e2. doi:10.1053/j.gastro.2016.09.060.
8. Cowan RW, Maitra A. Genetic progression of pancreatic cancer. Cancer J. 2014;20(1):80–84. doi:10.1097/PPO.0000000000000011.
9. Genome Cancer Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615. doi:10.1038/nature10166.

10. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):841–848. doi:10.1038/nrd4389.

11. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varnerasian M, Ashbury P, Kaldjian EP, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22(22):4456–4462. doi:10.1200/JCO.2004.01.185.

12. Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damayanov D, Stella P, Ganchev L, Morris T, Tzekova V. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142868) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010;5(10):1630–1636. doi:10.1097/JTO.0b013e3181e8ba35.

13. Haura EB, Ricard AT, Larson TG, Stella P, Banhzeno L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010;16(8):2450–2457. doi:10.1158/1078-0432.CCR-09-1920.

14. O’Neil BH, Goff LW, Kauh JSW, Strosberg JR, Bekaii-Saab TS, Lee R-M, Kazi A, Moore DT, Learyod M, Lush RM, et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011;29(17):2350–2356. doi:10.1200/JCO.2010.33.9432.

15. Bodoky G, Timcheva C, Spigel DR, La Stella P, Ciuleanu TE, Pover G, Tebbutt NC. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142868]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 2012;30(3):1216–1223. doi:10.1007/s10637-011-9687-4.

16. Kirkwood JM, Britten CD. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol. 2013;71(6):1395–1405. doi:10.1007/s00280-013-2121-1.

17. Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2009;111(9):1788–1801. doi:10.1016/j.pharmthera.2009.12.004.

18. Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Hawkins WG, Derfler D, Goodman RA, Lockhart AC, et al. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PLoS One. 2013;8(10):e77243. doi:10.1371/journal.pone.0077243.

19. Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, et al. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget. 2017;8(27):44295–44311. doi:10.18632/oncotarget.17869.

20. Faber AC, Cook EM, Costa C, Dastur A, Ehi B, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov. 2014;4(1):42–52. doi:10.1158/2159-8290.CD-13-0315.

21. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Hawkins WG, Brown RD, Godfrey JT, Cohoon TJ, et al. Synthetic lethal interaction of combined BCL-2 and BCL-X(L) and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem. 2006;99(3):355–369.

22. Boucher MJ, Morisset J, Vachon PH, Reed JC, Lainé J, Rivard N, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, et al. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PLoS One. 2014;9(11):e101688. doi:10.1371/journal.pone.0101688.

23. Haugen JS, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moscicki AK, Newell DJ. Preclinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PIK3CA mutation status on MEK inhibitor activity is model dependent. Eur J Cancer. 2016;56:69–76. doi:10.1016/j.ejca.2015.12.012.

24. Nebihi A, Vahedie M, Pétigny-Lechwartier C, Brotin E, Louis MH, Abeillard E, Giffard F, Guercio M, Briand M, Gauduchon P, et al. PI3K/mTOR dual inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget. 2012;3(11):1416–1427. doi:10.18632/oncotarget.724.

25. Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, et al. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer. 2013;49(18):3936–3944. doi:10.1016/j.ejca.2013.08.007.

26. Zong Z, Sanchez C, Spitzer E, Plambeck-Sues S, Gibbs J, Hawkins WG, Derfler D, Goodman RA, Lockhart AC, et al. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PLoS One. 2013;8(10):e77243. doi:10.1371/journal.pone.0077243.
identifies a novel mechanism of drug resistance mediated by PDCD4. J Proteome Res. 2015;14(6):2480–2491. doi:10.1021/acs.jproteome.5b00004

35. Eto K, Goito S, Nakashima W, Ura Y, Abe S. Loss of programmed cell death 4 induces apoptosis by promoting the translation of p53ASIP mRNA. Cell Death Differ. 2012;19(4):573–581. doi:10.1038/cdd.2011.126.

36. Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS. Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 3. Cancer Res. 2011;71(16):5579–5587. doi:10.1158/0008-5472.CAN-11-0458.

37. Glienke W, Maute L, Wicht J, Bergmann L. The dual PI3K/mTOR signaling elicits pancreatic cancer cell growth through PI3K/Akt signaling in non-small cell lung cancer. J Mol Biol. 2015;427(2):61–67. doi:10.1016/j.jmb.2014.10.054.

38. Cheraghi-Bashi A, Parker CA, Curry E, Salazar JJ, Gungor H, et al. PI3K/Akt/mTOR pathway. J Biomol Screen. 2009;14(2):121–132. doi:10.1177/1087024108328132.

39. Wei N, Liu SS, Chan KK, Ngan HY. Tumour suppressor gene expression in human pancreatic cancer cell lines. Mol Cancer Ther. 2010;9(3):742–750. doi:10.1158/1535-7163.MCT-10-0767.

40. Lee WS, Park YL, Kim N, Oh HH, Son DJ, Kim MY, Oak CY, et al. PI3K/Akt signaling in non-small cell lung cancer. Mol Cancer. 2009;8:70. doi:10.1186/1476-4598-8-70.

41. Ma G, Zhang H, Dong M, Zheng X, Ozaki I, Matsuhashi S, Guo K. Downregulation of programmed cell death 4 (Pdc4d4) associates with the progression of ovarian cancer. Mol Cancer. 2009;8:70. doi:10.1186/1476-4598-8-70.

42. Song X, Zhang X, Wang X, Zhu F, Guo G, Wang Q, Shi Y, Wang J, Chen Y, Zhang L. Tumor suppressor gene PDCD4 negatively regulates autophagy by inhibiting the expression of autophagy-related gene ATG5. Autophagy. 2013;9(5):745–753. doi:10.4161/auto.24069.

43. Chen Y, Li D, Li W, Yao W, Wu A, Huang J, Gu H, Huang Y, Wang Y, Wu J, et al. Reduced PDCD4 expression promotes cell growth through PI3K/Akt signaling in non-small cell lung cancer. Oncol Res. 2016;23(1–2):61–68. doi:10.3727/096504015X6487843952861.

44. Dorrello NV, Peschiarioli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 2006;314(5798):467–471. doi:10.1126/science.1130276.

45. Matsumoto S, Hamajima H, Xia J, Zhang H, Mizuta T, Anzai K, Ozaki I. Control of a tumor suppressor PDCD4: degradation mechanisms of the protein in hepatocellular carcinoma cells. Cell Signal. 2014;26(3):603–610. doi:10.1016/j.cellsig.2013.11.038.

46. Vikhareva PN, Shepelev MV, Korobko IV. mTOR-dependent transcriptional repression of Pdc4d4 tumor suppressor in lung cancer cells. Biochem Pharmacol. 2014;83(1):43–49. doi:10.1016/j.bcp.2013.12.001.

47. Xu H, Dephoure N, Sun H, Zhang H, Fan F, Liu J, Ning X, Dai S, Liu B, Gao M, et al. Proteomic profiling of paclitaxel treated cells identifies a novel mechanism of drug resistance mediated by PDCD4. J Proteome Res. 2015;14(6):2480–2491. doi:10.1021/acs.jproteome.5b00004.

48. Storacchi M, Chen M, Maginn EN, Garrawal R, Mills GB, Wasan H, Gabra H. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia. 2013;11(11):1069. doi:10.1593/neo.130808.

49. Fouquer J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3):e00149. doi:10.1002/prp2.149.